



Elevidys in UAE

The MoHAP named-patient coordination pathway — indicative 2026

RARE DISEASE · DUCHENNE MUSCULAR DYSTROPHY

The clinical situation

Elevidys (delandistrogene moxeparvovec-rokl) is an FDA-approved one-time AAV-rh74-based gene therapy that delivers a shortened micro-dystrophin transgene to skeletal muscle for ambulatory and non-ambulatory patients with Duchenne muscular dystrophy (DMD) with a confirmed DMD gene mutation. Manufactured by Sarepta Therapeutics. Anti-AAVrh74 antibody testing, corticosteroid pre-treatment, and post-infusion liver-enzyme and troponin monitoring are required around the single IV administration.

The pathway, 5 steps

- 1 Consultation & genetic confirmation.** Treating paediatric neurologist confirms DMD mutation, ambulatory status, and negative anti-AAVrh74 antibody screen; weight-based dose calculated.
- 2 Infusion centre confirmed.** A UAE tertiary paediatric centre (Abu Dhabi or Dubai) with cold-chain handling and post-infusion monitoring capacity accepts the case.
- 3 MoHAP named-patient application.** Clinical rationale, mutation report, antibody result, informed consent, and chain-of-custody plan are filed with MoHAP.
- 4 US-side sourcing & cold-chain logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner, frozen-chain shipment booked to infusion date.
- 5 Infusion & post-infusion monitoring.** Single IV infusion under neurologist supervision; steroid protocol and weekly liver-enzyme / troponin monitoring for 3 months post-dose.

Indicative economics

Reference US list-price range: USD 3.0–3.5M one-time drug-only. Frozen-chain logistics, MoHAP documentation, infusion centre fees, and concierge coordination are incremental. Full transparent quote at intake.

Indicative intake-to-infusion timing

6–10 weeks from a complete MoHAP application to infusion-day delivery, once cohort intake opens. Indicative — not guaranteed.

Reserve Meds's role

Sourcing. US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** MoHAP regulatory package including antibody screen and genetic report. **Logistics.** Frozen-chain, temperature-monitored shipment coordination to the infusion centre. **Concierge case lead.** Named point of contact for family and physician through the full process. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with the treating neurologist and infusion centre.

COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST

Join the Elevidys × UAE first-cohort waitlist. *Our concierge reaches out as we open intake.*

reservemed.com/access-guides/elevidys-uae.html



SCAN TO JOIN

Reserve Meds · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.

reservemed.com · hello@reservemed.com · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team